LT3004166T - Alergeno atžvilgiu specifinės imunoterapijos sustiprinimo būdai, įvedant il-4r inhibitorių - Google Patents

Alergeno atžvilgiu specifinės imunoterapijos sustiprinimo būdai, įvedant il-4r inhibitorių

Info

Publication number
LT3004166T
LT3004166T LTEP14733922.0T LT14733922T LT3004166T LT 3004166 T LT3004166 T LT 3004166T LT 14733922 T LT14733922 T LT 14733922T LT 3004166 T LT3004166 T LT 3004166T
Authority
LT
Lithuania
Prior art keywords
administering
inhibitor
methods
specific immunotherapy
allergen
Prior art date
Application number
LTEP14733922.0T
Other languages
English (en)
Lithuanian (lt)
Inventor
Neil Stahl
Jamie ORENGO
Andrew Murphy
Namita GANDHI
Neil Graham
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3004166T publication Critical patent/LT3004166T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
LTEP14733922.0T 2013-06-04 2014-06-03 Alergeno atžvilgiu specifinės imunoterapijos sustiprinimo būdai, įvedant il-4r inhibitorių LT3004166T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361830919P 2013-06-04 2013-06-04
PCT/US2014/040695 WO2014197470A1 (en) 2013-06-04 2014-06-03 Mehods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

Publications (1)

Publication Number Publication Date
LT3004166T true LT3004166T (lt) 2019-12-27

Family

ID=51023185

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14733922.0T LT3004166T (lt) 2013-06-04 2014-06-03 Alergeno atžvilgiu specifinės imunoterapijos sustiprinimo būdai, įvedant il-4r inhibitorių

Country Status (25)

Country Link
US (5) US10392439B2 (OSRAM)
EP (2) EP3617233A1 (OSRAM)
JP (6) JP6499167B2 (OSRAM)
KR (3) KR102580468B1 (OSRAM)
CN (3) CN105377894A (OSRAM)
AU (3) AU2014275094C1 (OSRAM)
CA (1) CA2914203C (OSRAM)
CY (1) CY1124095T1 (OSRAM)
DK (1) DK3004166T3 (OSRAM)
ES (1) ES2767080T3 (OSRAM)
HR (1) HRP20200185T1 (OSRAM)
HU (1) HUE048655T2 (OSRAM)
IL (3) IL312710A (OSRAM)
LT (1) LT3004166T (OSRAM)
MX (2) MX384112B (OSRAM)
NZ (1) NZ630183A (OSRAM)
PL (1) PL3004166T3 (OSRAM)
PT (1) PT3004166T (OSRAM)
RS (1) RS59883B1 (OSRAM)
RU (1) RU2679920C2 (OSRAM)
SG (3) SG10201709670XA (OSRAM)
SI (1) SI3004166T1 (OSRAM)
TW (3) TWI697334B (OSRAM)
WO (1) WO2014197470A1 (OSRAM)
ZA (1) ZA201508174B (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PT3470432T (pt) 2012-08-21 2021-12-14 Regeneron Pharma Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r
BR112015005048A8 (pt) 2012-09-07 2018-01-30 Regeneron Pharma métodos para tratar dermatite atópica por administração de antagonista il-4r
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20210132232A (ko) 2013-06-21 2021-11-03 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
JP6526037B2 (ja) 2014-02-28 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
EP3218412A1 (en) 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
HK1250514A1 (zh) * 2015-04-02 2018-12-21 Intervet International B.V. 针对犬白介素-4受体α的抗体
EP3390451B1 (en) * 2015-12-18 2025-01-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
AU2017220184B2 (en) * 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
EP3423453A4 (en) * 2016-03-01 2019-11-06 Corcept Therapeutics, Inc. USE OF GLUCOCORTICOID RECEPTOR MODULATORS TO POTENTIALIZE CHECKPOINT INHIBITORS
KR20230041834A (ko) 2016-08-16 2023-03-24 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
CA3035202A1 (en) * 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
IL265195B2 (en) * 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
AU2017350807B2 (en) 2016-10-25 2022-07-07 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
JP7301043B2 (ja) 2017-09-19 2023-06-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 粒子の形成を低減する方法及びそれにより形成される組成物
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US11460452B2 (en) * 2017-12-13 2022-10-04 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
WO2019148405A1 (zh) * 2018-02-01 2019-08-08 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
JP2021522241A (ja) * 2018-04-25 2021-08-30 キニクサ ファーマシューティカルズ， リミテッド 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療
TWI814812B (zh) 2018-05-02 2023-09-11 美商里珍納龍藥品有限公司 用於評估生化過濾器的適合性的方法
JP2021523188A (ja) 2018-05-13 2021-09-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
US11448651B2 (en) * 2018-07-10 2022-09-20 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-exisiting interactions
AU2019338602A1 (en) * 2018-09-14 2021-04-01 Elanco Us Inc. Anti-IL4 receptor antibodies for veterinary use
EP3878868B1 (en) 2018-11-09 2024-10-09 Ajou University Industry-Academic Cooperation Foundation Human antibody having high affinity to human il-4 receptor alpha, and use thereof
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
EA202191806A1 (ru) * 2018-12-27 2021-11-09 Акесо Байофарма, Инк. Антитело против человеческого il-4ra и его применение
RU2700788C1 (ru) * 2019-01-17 2019-09-23 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ оценки эффективности проведения аллерген-специфической иммунотерапии при аллергическом рините
CN121102493A (zh) 2019-03-21 2025-12-12 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
CA3147436A1 (en) 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
WO2021026203A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
MX2022001247A (es) 2019-08-05 2022-04-25 Regeneron Pharma Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
JP2023502423A (ja) * 2019-11-20 2023-01-24 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 食物アレルギー経口免疫療法薬物の配給及び治療を管理する方法及びシステム
CA3161037A1 (en) 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CN113527485B (zh) 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN116348605A (zh) * 2020-07-17 2023-06-27 Gi 医诺微新 包含IgE Fc受体α亚基胞外结构域和抗IL-4R抗体的融合蛋白及其应用
KR20230130681A (ko) * 2021-01-08 2023-09-12 리제너론 파아마슈티컬스, 인크. Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법
WO2023009437A1 (en) * 2021-07-26 2023-02-02 Sanofi Biotechnology Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
CN115960236B (zh) * 2023-01-05 2024-08-06 江苏荃信生物医药股份有限公司 一种定量检测血清中抗人白介素4受体α单克隆抗体含量的酶联免疫分析方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
AU665763B2 (en) 1991-05-03 1996-01-18 Seragen, Inc. Interleukin receptor targeted molecules for treatment of inflammatory arthritis
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
EP1113818B1 (en) 1998-09-18 2006-05-17 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
EP1283851B1 (en) 2000-05-26 2012-03-28 Immunex Corporation Use of il-4r antibodies and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR100572408B1 (ko) 2000-07-26 2006-04-19 가부시키가이샤 호오도 진양성 조성물 및 창상치유촉진 조성물
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
BR0117009A (pt) 2001-05-11 2004-04-20 Novartis Ag Composiçoes para utilização no tratamento de distúrbios associados a ige
JP4339598B2 (ja) 2001-05-23 2009-10-07 デュオトール アーベー 毒素サブユニットまたはそのフラグメントと共に、又はこれとコンジュゲートされたアレルゲンの経皮投与によるアレルギー反応の抑制
WO2003048083A2 (en) 2001-11-30 2003-06-12 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
CN1326879C (zh) 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
CA2514839A1 (en) 2003-02-01 2004-08-19 Tanox, Inc. A method for generating high affinity antibodies
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
WO2005085284A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 sepecific polypetides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
MX2009003393A (es) 2006-10-02 2009-05-11 Regeneron Pharma Anticuerpos humanos de alta afinidad para el receptor de il-4 humano.
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR101555068B1 (ko) 2007-03-22 2015-10-06 제넨테크, 인크. 막 결합형 ｉｇｅ에 결합하는 세포자멸성 항-ｉｇｅ 항체
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
CA2748712A1 (en) 2008-12-01 2010-06-10 Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
US20120088814A1 (en) 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
CN102596237A (zh) 2009-09-07 2012-07-18 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
EP2585075B8 (en) 2010-06-24 2021-09-22 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
PH12013500672A1 (en) 2010-10-06 2013-06-03 Regeneron Pharma Stabilized formulations containing anti-interleukin-4-receptor (il-4r) antibodies
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
WO2012094643A2 (en) 2011-01-06 2012-07-12 Children's Hospital Medical Center Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
EP2723899B1 (en) 2011-06-21 2020-11-18 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
EP2763683A1 (en) 2011-10-06 2014-08-13 N.V. Nutricia Treatment of eosinophilic esophagitis
MX2014007239A (es) 2011-12-16 2014-08-08 Atopix Therapeutics Ltd Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica.
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
PT3470432T (pt) 2012-08-21 2021-12-14 Regeneron Pharma Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r
BR112015005048A8 (pt) * 2012-09-07 2018-01-30 Regeneron Pharma métodos para tratar dermatite atópica por administração de antagonista il-4r
WO2014059178A1 (en) 2012-10-10 2014-04-17 Rhode Island Hospital Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis
PL2953972T3 (pl) 2013-02-05 2021-03-08 Engmab Sàrl Metoda wyboru przeciwciał przeciwko bcma
TWI697334B (zh) * 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20210132232A (ko) 2013-06-21 2021-11-03 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
JP6526037B2 (ja) 2014-02-28 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法
EP3218412A1 (en) 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
AU2017220184B2 (en) 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CA3035202A1 (en) 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
CA3037499A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
JP2021523188A (ja) 2018-05-13 2021-09-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
CN121102493A (zh) 2019-03-21 2025-12-12 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
WO2021026203A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
MX2022001247A (es) 2019-08-05 2022-04-25 Regeneron Pharma Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
CA3161037A1 (en) 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
BR112022022235A2 (pt) 2020-05-22 2023-03-28 Regeneron Pharma Métodos para tratamento de esofagite eosinofílica através da administração de inibidor de il-4r

Also Published As

Publication number Publication date
AU2014275094B2 (en) 2019-03-28
DK3004166T3 (da) 2020-01-06
CA2914203A1 (en) 2014-12-11
PL3004166T3 (pl) 2020-06-01
HK1216898A1 (en) 2016-12-09
TWI633891B (zh) 2018-09-01
US11485788B2 (en) 2022-11-01
RU2015156628A (ru) 2017-07-14
JP2023103389A (ja) 2023-07-26
RU2019103601A (ru) 2019-03-12
KR102580468B1 (ko) 2023-09-21
JP2025011257A (ja) 2025-01-23
CN105377894A (zh) 2016-03-02
TWI697334B (zh) 2020-07-01
CY1124095T1 (el) 2022-03-24
JP2022101613A (ja) 2022-07-06
RU2679920C2 (ru) 2019-02-14
RU2015156628A3 (OSRAM) 2018-05-30
JP2016521713A (ja) 2016-07-25
JP7284313B2 (ja) 2023-05-30
US10669341B2 (en) 2020-06-02
EP3617233A1 (en) 2020-03-04
KR20230017923A (ko) 2023-02-06
TW202038999A (zh) 2020-11-01
US10392439B2 (en) 2019-08-27
JP6754857B2 (ja) 2020-09-16
KR20160014626A (ko) 2016-02-11
SI3004166T1 (sl) 2020-02-28
ZA201508174B (en) 2017-09-27
CA2914203C (en) 2024-04-16
AU2021229250A1 (en) 2021-10-07
HRP20200185T1 (hr) 2020-05-01
RS59883B1 (sr) 2020-03-31
KR102355114B1 (ko) 2022-01-27
MX2015016473A (es) 2016-03-03
PT3004166T (pt) 2020-01-14
NZ630183A (en) 2018-10-26
CN117982639A (zh) 2024-05-07
TW201519905A (zh) 2015-06-01
SG10201913835XA (en) 2020-03-30
US20230159647A1 (en) 2023-05-25
SG11201509044QA (en) 2015-12-30
AU2014275094A1 (en) 2015-12-17
IL273678B2 (en) 2024-10-01
IL273678B1 (en) 2024-06-01
IL273678A (en) 2020-05-31
HUE048655T2 (hu) 2020-08-28
US20180094070A1 (en) 2018-04-05
JP7061163B2 (ja) 2022-04-27
TWI755763B (zh) 2022-02-21
TW201906630A (zh) 2019-02-16
US10676530B2 (en) 2020-06-09
JP6499167B2 (ja) 2019-04-10
MX384112B (es) 2025-03-14
AU2021229250B2 (en) 2024-11-14
CN118001391A (zh) 2024-05-10
KR102492826B1 (ko) 2023-01-30
IL242456B (en) 2020-04-30
EP3004166B1 (en) 2019-11-20
US20180094069A1 (en) 2018-04-05
AU2019204577A1 (en) 2019-07-18
KR20220011810A (ko) 2022-01-28
SG10201709670XA (en) 2018-01-30
AU2014275094C1 (en) 2019-10-10
MX2021002173A (es) 2021-04-28
US20140356372A1 (en) 2014-12-04
JP7575526B2 (ja) 2024-10-29
WO2014197470A1 (en) 2014-12-11
IL312710A (en) 2024-07-01
JP2020193218A (ja) 2020-12-03
AU2019204577B2 (en) 2021-06-24
EP3004166A1 (en) 2016-04-13
US20200299393A1 (en) 2020-09-24
ES2767080T3 (es) 2020-06-16
JP2019112440A (ja) 2019-07-11

Similar Documents

Publication Publication Date Title
LT3004166T (lt) Alergeno atžvilgiu specifinės imunoterapijos sustiprinimo būdai, įvedant il-4r inhibitorių
IL289821A (en) Preparations and methods for immunotherapy
SG11201507688VA (en) Compositions and methods for immunotherapy
PL2984871T3 (pl) Operacja pdcp w celu podwójnego połączenia
ZA201600441B (en) Activator for an autoinjector
EP2949994A4 (en) COMBUSTION APPARATUS
ZA201506156B (en) Novel inhibitors
IL240753A0 (en) Antibody purification methods
GB201312133D0 (en) Immunotherapy
IL243235A0 (en) Preparations and methods for immunotherapy
IL242803A0 (en) Dihydropyridinones as mgat2 inhibitors
EP2994143A4 (en) Stat6 inhibitors
IL242623A0 (en) Pyrrolotriazines as alk inhibitors
GB2517980B (en) Combustion apparatus
EP3101341A4 (en) Combustion apparatus
EP2945930A4 (en) Novel ddp-iv inhibitors
GB201320835D0 (en) HIF inhibitors
PL2886957T3 (pl) Urządzenie do spalania